Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboprost is a synthetic analogue of prostaglandin F2-alpha used primarily as a uterotonic agent. It induces strong myometrial contractions by binding to the prostaglandin E2 receptor, leading to expulsion of uterine contents and hemostasis at the placental site. Clinically, it is indicated for the treatment of severe postpartum hemorrhage due to uterine atony when other interventions have failed and for inducing abortion in the second trimester (typically between weeks 13–20), especially when other methods are incomplete or contraindicated. Carboprost also stimulates smooth muscle in the gastrointestinal tract and may cause side effects such as vomiting or diarrhea[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboprost.